Key Takeaways
- Transformation delivering, but early: A 10-month business model overhaul toward insulin and partnerships has begun to lift top and bottom lines, with growth accelerating in Q3. The full-year comparability reset only arrives in 2026.
- Export revenue fell as planned, profit impact muted: The drop was expected after the Ankleshwar divestment, and management explicitly stated it will not recover 100% of what was lost. Because export margins are lower than domestic, the profit hit is small.
- OPEX optimization drove the quarter: Personnel and other OPEX fell 30% versus last quarter, with the ratio improving to 22%, a significant contributor to PBT. One month of restructuring savings was realized; more will accrue quarter by quarter.
- No new launches in 2026: Management confirmed no new products are expected next year, citing a cautious approach to global products that may be too expensive for Indian patients and a >50% failure rate for Indian launches. Organic growth from the current portfolio is described as respectable.
- What to watch next quarter: The pace of employee cost savings as the restructuring flows through, whether the partnership portfolio sustains its volume-led growth, and any progress on Dupixent finalization or the type 1 diabetes product evaluation.
Business Model Transformation
- Insulin-focused, customer-centric redesign: Over the last 10 months, the company refined its structure and go-to-market strategy to concentrate on the insulin franchise, supported by digital empowerment. The transformation is already showing positive results in both top line and bottom line, with growth accelerating in Q3.
- Legacy portfolios moved to partnerships: Cardiovascular, CNS and oral anti-diabetic products were positioned into a partnership model, leveraging partners' capabilities and networks. Partnership performance is tracking to the trend expected at signing.
- Partnership financial mechanics: The Emcure partnership for oral anti-diabetes uses a gross-to-net model where the partner distributes and promotes, which subdues reported domestic growth. Secondary sales are somewhat higher than the reported 2%, but management cannot disclose specifics. Growth from the partnership will build year over year, not immediately.
- Partnership growth expectations are measured: Double-digit growth is not expected given a highly competitive market. The partnerships have accelerated growth compared to in-house promotion, and volume growth has compensated for the gross-to-net downside. The model also unlocks Tier 2 and Tier 3 cities that were previously out of reach.
- Restructuring charge booked: An INR 27 crore one-off exceptional charge related to the transformation and the Emcure partnership was booked in Q3.
Eric Mansion: "This year is pivotal for Sanofi India Limited, and we have completely transformed and modernized our business model with the aim to strengthen our leadership in the insulin market and to re-position ourselves with sustainable and profitable growth."
Export Reset
- Decline was expected and structural: The export drop relates to the 2020 divestment of the Ankleshwar site to Zentiva. Zentiva continued manufacturing at Sanofi's Goa site pending Indian regulatory authorization, which was obtained at the end of 2024, triggering the volume shift.
- Offset plan underway but partial: Management is increasing volume at the Goa site and adding new export markets, including Russia and South Africa. Certain products previously sold in India are being moved to the Goa site. However, the company will not cover 100% of what was lost.
- Profit impact contained: Despite a significant decrease in export revenues, the impact on profit is not significant because export profitability is lower than domestic. Export represents around 8% of total profit before tax; the major profit contribution comes from the higher-margin domestic business.
- Russia exports now routine: First budget exports to Russia started at the end of last year and have become routine. South Africa is in the export plan.
Rachid Ayari: "But despite the fact, what I can assure you the fact that this impact is significant in the top line, but in the bottom line, it is not because the export in terms of profitability versus the domestic... domestic segment."
OPEX & Margin Trajectory
- Sharp OPEX reduction this quarter: Personnel cost and other OPEX fell 30% versus last quarter, with the OPEX ratio improving to 22%. This was a significant contributor to PBT.
- Restructuring savings to build: One month of personnel cost savings was realized in the quarter from the transformation. Savings will increase quarter over quarter going forward, and the decrease should not be linked to the one-off restructuring charge.
- OPEX trend is structurally lower: Management stated OPEX will not increase; significant optimization and efficiency are being sought year over year. The expectation is for an improving ratio versus net sales in upcoming years if the current trajectory holds.
Insulin Portfolio & Competitive Dynamics
- Soliqua acceleration is the near-term priority: Launched less than 1.5 years ago, Soliqua has been very successful so far, and accelerating its uptake is the immediate focus. For at least 1.5 years, the emphasis will be on driving diabetes performance with Toujeo and Soliqua.
- Biosimilar threat receding for Lantus: After Lantus was brought under NLEM, biosimilar prices are now equivalent to the innovator product. Management believes doctors are losing interest in biosimilars when Lantus is available at the same price, and the impact will favor the innovator.
- Toujeo expansion into public sector: A new go-to-market model is being deployed to tap public sector potential for Toujeo (U300), where there is no competition, in addition to the private sector.
- GLP-1 oral competition not seen displacing insulin initiation: Based on HCP discussions, management believes oral GLP-1s target a different segment and are not replacing insulin initiation.
- Type 1 diabetes product still under evaluation: The company is assessing access conditions and the environment that needs to be shaped before launching, wanting to be successful rather than launching prematurely.
Eric Mansion: "And considering the fact that biosimilar prices are equivalent to Lantus now after the NLEM of Lantus, the need for using biosimilars for the doctors is slowly, I would say, losing interest with Lantus available at the same price being an innovator."
Product Pipeline & Launch Caution
- No new launches in 2026: Business cases are under validation, but nothing is expected next year. Organic growth from the current portfolio is described as respectable versus the market.
- Cautious approach to global products: Management noted that some global products may be too expensive for Indian patients, and the failure rate for Indian company launches exceeds 50%. The focus is on not failing when launching, which means evaluating access conditions carefully.
- Dupixent still not finalized: Despite considerable discussion, the launch decision for Dupixent in India remains unresolved.
- Beyfortus launched outside Sanofi India Limited: Beyfortus was launched in Sanofi's private legal entity in India, not in the listed entity, because there is no synergy between the two portfolios.
Rachid Ayari: "Now regarding certain products that we have in the portfolio at the global level in terms of price, I'm not sure that the Indian patient can offer such product."
AI & Digital
- AI deployed across the organization: Generative AI is used for marketing tools, AI tools guide the sales force on next best actions, AI supports finance with reports and recommendations, and AI streamlines regulatory submission timing.
- Forecasting accuracy improved materially: AI-driven forecasting has reached plus/minus 1% versus reality, avoiding significant obsolescence (now less than 1%) and reducing lost opportunity from under-forecasting. Management cannot quantify the exact financial impact on top or bottom line.
- Technology team leverages global scale: Sanofi India has a local technology team but relies heavily on the global group for standard solutions. Management declined to isolate the local technology cost or team size, citing the distributed nature of the IT function.
Eric Mansion: "We are really leveraging on AI wherever we can... we are really all in on AI, and we are trying to empower all Sanofian with the right tools in order to amplify the capabilities and make sure that we create value."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Export recovery ceiling | Will not cover 100% of lost export revenue | Ongoing |
| No new product launches | No new products expected; business cases under validation | Calendar 2026 |
| OPEX trajectory | OPEX will not increase; optimization and efficiency sought year over year | Ongoing |
| Personnel cost savings | Savings will increase quarter over quarter from the restructuring | Next several quarters |
| Full-year comparability | Transformation will be comparable apple-to-apple | 2026 |
| Diabetes focus | Accelerate Toujeo and Soliqua performance for at least 1.5 years | At least 1.5 years |
| Margin expansion | Expecting improvement in OPEX ratio versus net sales if current trajectory holds | Upcoming years |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations (sales) | 93% to 94% of total revenue |
| Diabetes insulin portfolio growth | +5% quarter-to-quarter vs last year |
| Partnership portfolio growth | +5% quarter-to-quarter |
| Exports as a share of total sales | 12% to 13% |
| OPEX (personnel and other) change | -30% vs last quarter |
| OPEX ratio to sales | 22% |
| Export profit contribution | ~8% of total profit before tax |
| Profit before tax growth (Q3 vs Q3 2024) | Double-digit growth |
| PBT to net sales ratio | 29%, improved from 23% in Q3 2024 |
| Operating margin | ~28% this quarter |
| Interim dividend | ₹75 per share for YTD September |
| Employee costs | ~₹42 cr, down from ~₹56 cr last quarter |
| Exceptional item (VRS restructuring) | ₹27 cr booked in Q3 |
| India revenue contribution | 81% of total revenue |
| Obsolescence rate | ~1%, improved from higher levels in the past |